Pfizer-Allergan and the new U.S. tax inversion rule

A potential $160 billion merger between Pfizer and Allergan may be put in jeopardy by new steps taken by the U.S. government to limit tax-cutting in corporate inversions. Bloomberg's Intelligence's Sam Fazeli explains on "Bloomberg GO."